Abstract:Although, by age 40, individuals with Down syndrome (DS) develop amyloid-β (Aβ) plaques and tau-containing neurofibrillary tangles (NFTs) linked to cognitive impairment in Alzheimer’s disease (AD), not all people with DS develop dementia. Whether Aβ plaques and NFTs are associated with individuals with DS with (DSD +) and without dementia (DSD −) is under-investigated. Here, we applied quantitative immunocytochemistry and fluorescent procedures to characterize NFT pathology using antibodies specific for tau phosphorylation (pS422, AT8), truncation (TauC3, MN423), and conformational (Alz50, MC1) epitopes, as well as Aβ and its precursor protein (APP) to frontal cortex (FC) and striatal tissue from DSD + to DSD − cases. Expression profiling of single pS422 labeled FC layer V and VI neurons was also determined using laser capture microdissection and custom-designed microarray analysis. Analysis revealed that cortical and striatal Aβ plaque burdens were similar in DSD + and DSD − cases. In both groups, most FC plaques were neuritic, while striatal plaques were diffuse. By contrast, FC AT8-positive NFTs and neuropil thread densities were significantly greater in DSD + compared to DSD −, while striatal NFT densities were similar between groups. FC pS422-positive and TauC3 NFT densities were significantly greater than Alz50-labeled NFTs in DSD + , but not DSD − cases. Putaminal, but not caudate pS422-positive NFT density, was significantly greater than TauC3-positive NFTs. In the FC, AT8 + pS422 + Alz50, TauC3 + pS422 + Alz50, pS422 + Alz50, and TauC3 + pS422 positive NFTs were more frequent in DSD + compared to DSD- cases. Single gene-array profiling of FC pS422 positive neurons revealed downregulation of 63 of a total of 864 transcripts related to Aβ/tau biology, glutamatergic, cholinergic, and monoaminergic metabolism, intracellular signaling, cell homeostasis, and cell death in DSD + compared DSD − cases. These observations suggest that abnormal tau aggregation plays a critical role in the development of dementia in DS.

P4-064 Increased BACE1 Maturation in Down Syndrome

Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome.

BACE2, As a Novel APP Θ‐secretase, is Not Responsible for the Pathogenesis of Alzheimer's Disease in Down Syndrome

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

γ‐Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer‐Related Pathologies in a Mouse Model of Down Syndrome

PS1 Affects the Pathology of Alzheimer’s Disease by Regulating BACE1 Distribution in the ER and BACE1 Maturation in the Golgi Apparatus

Amyloid-β Precursor Protein Facilitates the Regulator of Calcineurin 1-Mediated Apoptosis by Downregulating Proteasome Subunit Α Type-5 and Proteasome Subunit Β Type-7.

Reduced synaptic proteins and SNARE complexes in Down syndrome with Alzheimer's disease and the Dp16 mouse Down syndrome model: Impact of APP gene dose

Distinct Molecular Signatures of Amyloid-Beta and Tau in Alzheimer's Disease Associated with Down Syndrome

A Novel Mechanism Underlying Pathogenesis of Down Syndrome

Amyloid Precursor Protein-Mediated Endocytic Pathway Disruption Induces Axonal Dysfunction and Neurodegeneration.

Common genetic signatures of Alzheimer's disease in Down Syndrome

Beta Secretase Localization, Amyloid Deposition And Aberrant Synaptic And Neuritic Sprouting In Transgenic Mouse Alzheimer Models: A Role For Bace1 In Synaptic Remodeling And Plaque Formation?

Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP

Exosomal biomarkers in Down syndrome and Alzheimer's disease

Associations of CSF BACE1 with Amyloid Pathology, Neurodegeneration, and Cognition in Alzheimer’s Disease

Inhibition of Sphingomyelin Synthase 1 Ameliorates Alzheimer-Like Pathology in APP/PS1 Transgenic Mice Through Promoting Lysosomal Degradation of BACE1

A Review of Biomarkers for Alzheimer’s Disease in Down Syndrome

Hypoxia Facilitates Alzheimer's Disease Pathogenesis by Up-Regulating BACE1 Gene Expression

Frontal Cortex and Striatal Cellular and Molecular Pathobiology in Individuals with Down Syndrome with and Without Dementia

Regulation Of Ss-Site App-Cleaving Enzyme 1 Gene Expression And Its Role In Alzheimer'S Disease